Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
- D. Slamon, B. Leyland-Jones, L. Norton
- MedicineNew England Journal of Medicine
- 15 March 2001
The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
- S. Paik, S. Shak, N. Wolmark
- MedicineNew England Journal of Medicine
- 30 December 2004
The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for…
- M. Cobleigh, C. Vogel, D. Slamon
- Medicine, BiologyJournal of Clinical Oncology
- 1 September 1999
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
- C. Vogel, M. Cobleigh, M. Press
- Medicine, BiologyJournal of Clinical Oncology
- 1 February 2002
Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
- S. Paik, G. Tang, N. Wolmark
- MedicineJournal of Clinical Oncology
- 10 August 2006
The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Cardiac dysfunction in the trastuzumab clinical trials experience.
- A. Seidman, C. Hudis, D. Keefe
- MedicineJournal of Clinical Oncology
- 1 March 2002
Trastuzumab is associated with an increased risk of cardiac dysfunction, which is greatest in patients receiving concurrent anthracyclines, and in most patients with metastatic breast cancer, the risk of CD can be justified given the improvement in overall survival previously reported with trastuzUMab.
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
- M. Gordon, K. Margolin, D. Adelman
- Medicine, BiologyJournal of Clinical Oncology
- 1 February 2001
Multiple doses of rhuMAb VEGF were well tolerated, and pharmacokinetic studies indicate that doses of > or = 0.3 mg/kg have a half-life similar to that of other humanized antibodies.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
- E. Mamounas, G. Tang, N. Wolmark
- Medicine, BiologyJournal of Clinical Oncology
- 1 April 2010
A significant association exists between RS and risk for locoregional recurrence (LRR) in patients with node-negative, ER-positive breast cancer from two National Surgical Adjuvant Breast and Bowel Project trials and in multivariate analysis, RS was an independent significant predictor of LRR along with age and type of initial treatment.
...
...